Rule 3.19A.2

# **Appendix 3Y**

# **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Antisense Therapeutics Limited (ASX: ANP)
ABN 41 095 060 745

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mark Diamond
Date of last notice	o2 November 2018

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct		
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	-		
Date of change	18 December 2019		
No. of securities held prior to change		Shares	Options
	Direct	3,600,000	642,772
	Indirect	-	-
	Total	3,600,000	642,772
Class	Ordinary sh	ares	
Number acquired	642,772		
Number disposed	Nil		
Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	\$51,422		

<sup>+</sup> See chapter 19 for defined terms.

No. of securities held after change			
		Shares	Options
	Direct	4,242,772	-
	Indirect	-	-
	Total	4,242,772	-
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back			

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change  Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration  Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

## Part 3 – \*Closed period

Were the interests in the securities or contracts detailed above	No
traded during a <sup>+</sup> closed period where prior written clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

E CFO

**The CFO Solution** 

18 December 2019

Appendix 3Y Page 2 01/01/2011

<sup>+</sup> See chapter 19 for defined terms.